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ABSTRACT
Objectives: Sequence variation within the COL5A1 and
TNC genes are known to associate with Achilles
tendinopathy. The primary aim of this case-control genetic
association study was to investigate whether variants
within the matrix metalloproteinase 3 (MMP3) gene also
contributed to both Achilles tendinopathy and Achilles
tendon rupture in a Caucasian population. A secondary
aim was to establish whether variants within the MMP3
gene interacted with the COL5A1 rs12722 variant to raise
risk of these pathologies.
Methods: 114 subjects with symptoms of Achilles
tendon pathology and 98 healthy controls were genotyped
for MMP3 variants rs679620, rs591058 and rs650108.
Results: As single markers, significant associations were
found between the GG genotype of rs679620 (OR = 2.5,
95% CI 1.2 to 4.90, p = 0.010), the CC genotype of
rs591058 (OR = 2.3, 95% CI 1.1 to 4.50, p = 0.023) and
the AA genotype of rs650108 (OR = 4.9, 95% CI 1.0 to
24.1, p = 0.043) and risk of Achilles tendinopathy. The
ATG haplotype (rs679620, rs591058, and rs650108) was
under-represented in the tendinopathy group when
compared to the control group (41% vs 53%, p = 0.038).
Finally, the G allele of rs679620 and the T allele of
COL5A1 rs12722 significantly interacted to raise risk of AT
(p = 0.006). No associations were found between any of
the MMP3 markers and Achilles tendon rupture.
Conclusion: Variants within the MMP3 gene are
associated with Achilles tendinopathy. Furthermore, the
MMP3 gene variant rs679620 and the COL5A1 marker
rs12722 interact to modify the risk of tendinopathy. These
data further support a genetic contribution to a common
sports related injury.
There is a spectrum of pathology that can affect
the Achilles tendon and surrounding structures.1
Achilles tendinopathy (AT) is one of these pathol-
ogies which is a painful and degenerative condition
that affects individuals who participate in a range
of sporting pursuits as well as the less physically
active.2 3 Acute spontaneous rupture is another
common pathology that can affect the Achilles
tendon, particularly in the middle-aged, male
athlete.4 A number of intrinsic and extrinsic factors
have been implicated in raising the risk of both AT
and Achilles tendon rupture.5
In recent years evidence has emerged that
Achilles tendon pathology has a genetic compo-
nent. For example, Mokone and colleagues have
identified that a GT repeat variant within the gene
that encodes the tenascin C protein (TNC), a key
constituent of tendon which is regulated by
mechanical loading,6 7 is associated with AT and
rupture.8 In addition to the TNC gene, polymorph-
isms within the 39-untranslated region of the
COL5A1 gene have also been associated with AT
in both South African9 and more recently an
Australian population.10 However, variation within
the Sp1 binding site of the COL1A1 gene does not
appear to associate with Achilles tendon pathol-
ogy,11 nor do polymorphisms within the related
COL14A1 and COL12A1 genes.12 Definitive bio-
chemical mechanisms that explain these observa-
tions are presently unknown and should form the
focus of future investigations.
In addition to the TNC and COL5A1 genes,
Achilles tendon pathology might also be associated
with genes that encode proteins with regulatory
roles in maintaining extracellular matrix (ECM)
homeostasis. Included in this class are the matrix
metalloproteinases (MMPs). The MMPs are known
to consist of over 20 distinct endopepdidases that
can catalyse a broad spectrum of both ECM and
non-ECM substrates.13 One of the family, MMP3,
can catalytically degrade multiple substrates
including: types II, IV, V, IX, X collagens, laminin,
fibronectin, proteoglycan, decorin and aggre-
can.13 14 MMP3 is also known to activate, via
propeptide removal, several other MMPs.13 15
Expression of the MMP3 gene can be substantially
altered by the 5A/6A promoter polymorphism16
and this variant has been associated with a number
of pathological states.17 18 Interestingly, reduced
levels of MMP3 mRNA19 20 and immunochemically
detectable MMP3 protein have been observed in
resected AT tissue compared to control tissue.20
Although there has been previous speculation
about the possible role of MMP genes in tendino-
pathy21 22 the hypothesis has, to our knowledge,
never been tested. Accordingly, the aim of this
investigation was to establish whether variants
within the MMP3 gene were associated with AT or
Achilles tendon rupture. A secondary aim was to
investigate whether MMP3 and COL5A1 gene-gene
interactions were involved in these Achilles tendon
pathologies.
MATERIALS AND METHODS
Subjects
In all, 114 Caucasian subjects diagnosed with
Achilles tendon injuries, including 75 with chronic
AT (TEN) using clinical criteria and 39 with partial
(n = 3) or complete ruptures of the Achilles tendon
(RUP), were recruited for this study from the
medical practice at the Sports Science Institute of
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South Africa and other clinical practices within the greater Cape
Town area of South Africa. Rupture of the Achilles tendon was
confirmed during surgery or by imaging. Ten of the subjects in
the RUP group had a history of tendinopathy. An additional 98,
apparently healthy, unrelated, Caucasian subjects without any
history of symptomatic Achilles tendon injuries were recruited
as controls (CON). The inclusion and exclusion criteria of the
participants have been previously described.8 9
Prior to participation in this study, the subjects gave informed
written consent and completed medical history questionnaire
forms. This study was approved by the Research Ethics
Committees of the Faculty of Health Sciences within the
University of Cape Town, South Africa and the University of
Northampton, England.
DNA extraction and single nucleotide polymorphism (SNP)
selection
DNA was extracted using the procedure described by Lahiri and
Nurnberger23 and modified by Mokone et al.8
Single nucleotide polymorphisms (SNPs) within the MMP3
gene and its 59-flanking sequence were identified from databases
hosted by the National Centre for Biotechnology Information
(NCBI) (http://www.ncbi.nlm.nih.gov/) and the International
HapMap project (http://www.hapmap.org/). The MMP3 gene
is transcribed in the negative orientation resulting in the mRNA
sequence corresponding to the bottom DNA strand. As
indicated in fig 1, the complimentary nucleotides are given in
the databases for some of the SNPs. These complementary
nucleotides are used in this manuscript to avoid confusion.
Seven exonic SNPs were identified and annotated onto a
schematic diagram (fig 1). Two of these SNPs were nonsyno-
nomous (SNPs which change the amino acid sequence in the
gene product), of which only one, rs679620 (E45K) within exon
2, has a high heterozygous frequency and could therefore be
potentially informative in genetic case-control association
studies. Two of the five synonomous SNPs, rs602128 (D96D)
within exon 2 and rs520540 (A362A) within exon 8, also have a
high heterozygous frequency and were therefore considered
potentially informative. From the databases hosted by the
International HapMap project these three exonic SNPs formed a
single haplotype block together with 4 informative (high
heterozygosity) intronic SNPs that spanned the entire gene
and a single informative SNP (rs645419) at -2 kb within the
promoter region (fig 1). The functional 5A/6A (rs3025058, -/T)
polymorphism, which is often used in association studies
involving the MMP3 gene17 18 is located downstream of SNP
rs645419. Four major haplotypes which contained these eight
potentially informative SNPs were identified using HaploView
V.4.124 and the HapMap CEU data (release 22). The same four
haplotypes with similar frequencies were also identified when
only three of the eights SNPs were analysed. In this study, the
MMP3 gene was therefore genotyped for SNPs (1) rs679620 a A/
G transition at nucleotide position 28 within exon 2, E45K; (2)
rs591058 a T/C transition at nucleotide position 1547 within
intron 4, and (3) rs650108 a G/A transition at position 495
within intron 8.
MMP3 SNP genotyping
DNA samples were genotyped for all three MMP3 variants
using fluorescence-based Taqman technology (Applied
Biosystems, Foster City, CA, USA). Allele specific probes and
flanking primer sets (table 1) were used along with a pre-made
PCR mastermix containing ampliTaq DNA polymerase Gold
(Applied Biosystems, Foster City, CA, USA) in a reaction
volume of 25 ml. PCR consisted of a 10 minute heat activation
step (95uC) followed by 40 cycles of 15 s at 92uC and 1 minute
Figure 1 A schematic representation of the exon (rectangles) and intron (horizontal lines) boundaries of the MMP3 (matrix metallopeptidase 3) gene,
which is located in the negative orientation on chromosome 11. The translated regions of the exons are solid while the untranslated regions (UTRs) are
clear. Exon numbers are indicated. The chromosomal location and the size of the gene are given in brackets. Single nucleotide polymorphisms (SNPs)
with high heterozygous frequencies (.20%) identified from databases hosted by the international HapMap project are annotated (clear boxes). In
addition, three synonomous, one nonsynonomous and a promoter (rs3025058, -/T) SNPs identified from databases hosted by the National Centre for
Biotechnology Information (NCBI) are also annotated (grey boxes). The three SNPs used in this study are annotated below the gene as clear boxes.
Accession numbers and base changes are indicated for all the SNPs. The minor alleles and, unless otherwise indicated, their frequencies from the
HapMap CEU population are also indicated. Where applicable the amino acid change and number of the exonic SNPs, as well as, the nucleotide position
of the two SNPs within the promoter region are indicated. All the information used to construct this figure was obtained from databases hosted by the
NCBI and Ensembl (http://www.ensembl.org/index.html) as well as from Beyzade et al.16 1The complementary nucleotides are given in the databases
and used in this manuscript to avoid confusion. 2Since frequency data was not available for the HapMap CEU population, minor allele frequency data
from other available European population data within the NCBI databases are indicated. 3Also referred to as the -1171 5A/6A polymorphism.
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at 60uC. PCR was performed on an MJ Miniopticon thermo-
cycler (BioRad Laboratories Inc, Herts, UK) and genotypes were
determined by endpoint fluorescence using MJ Monitor analysis
software (V.3.1).
Statistical analyses
Assuming an allele frequency of 0.43 (observed for MMP3) in
the CON group, group sizes of 97 in each group would be
adequate to detect an allelic odds ratio of at least 2.25 at a
power of 80% and significance level of 5%. Linear and logistic
regression models were used to assess difference between the
characteristics of the TEN, RUP and CON groups for
quantitative and categorical data, respectively. Logistic regres-
sion was used to compare the combined, as well as the separate
(TEN and RUP) Achilles tendon cases to the control groups,
with respect to genotype, allele and haplotype frequencies. Two
different methods were used to assess gene-gene interaction
between MMP3 and COL5A1 (SNP rs12722). Allele combina-
tions consisting of the markers on the two different genes were
constructed and their association with case-control status was
tested. The odds ratio based multifactor dimensionality reduc-
tion (ORMDR) method25 was also used to select from all SNPs,
the pair with the strongest association with tendinopathy. An
odds ratio (OR) is the quantitative measure of disease risk being
analysed but this is the estimated relative risk of disease with a
specific combination of genotypes. Data was analysed using the
freely available programming language R (http://www.r-pro-
ject.org/) and specifically packages DGC-genetics (LD, Hardy-
Weinberg, genotype and allelic association), haplo.stats
(inferred haplotype association) and ORMDR (interaction
between loci on case-control status). Pass2008 (http://www.
ncss.com/) was used for sample size calculation.
RESULTS
Subject characteristics
The TEN, RUP and CON groups were similarly matched for
age, height, gender and country of birth (table 2). The age of the
TEN and RUP groups was the age of initial onset of symptoms
of Achilles tendon injury, which were on average 7.8 (SD 8.0)
and 7.5 (SD 8.9) years prior to recruitment in this study
respectively. The reported weights were also at recruitment, not
at time of onset of injury. The TEN and RUP groups were on
average significantly heavier with corresponding higher BMI
than the CON group. In addition the RUP group was also on
average significantly heavier with corresponding higher BMI
than the TEN group. There were no MMP3 single nucleotide
polymorphism genotype effects on any of the subject char-
acteristics (results not shown).
Twenty six (38.2%) and five (13.5%) of the subjects were
diagnosed with bilateral chronic AT and Achilles rupture
respectively. Multiple Achilles tendon injuries (greater than
one) were documented in 16 (22.9%) and 13 (35.1%) of the TEN
and RUP subjects respectively. Forty four percent of the TEN
and 35% of the RUP subjects reported either a bilateral and/or
multiple Achilles tendon injury.
Genotype and allele frequencies
There were no significant differences in the genotype distribu-
tions of SNPs rs679620 (p = 0.064), rs591058 (p = 0.117) and
rs650108 (p = 0.132) between the Achilles tendon pathology
(combined TEN and RUP) and control groups (see figs 2A–C).
Similarly, there were no significant differences in the allele
distributions of SNPs rs679620 (p = 0.057), rs591058 (p = 0.083)
and rs650108 (p = 0.404) between the combined pathology and
control groups (figs 2D–F). Since differences have been detected
in genotype distributions between subjects with chronic AT or
Achilles tendon ruptures,12 the Achilles tendon pathology group
was sub-divided into tendinopathy (TEN) and rupture (RUP)
sub-groups. There were significant differences in the distribu-
tion of the genotype (p = 0.031) (fig 2A) and allele (p = 0.037)
(fig 2D) frequencies of the MMP3 rs679620 SNP between the
CON and TEN groups. The GG genotype was significantly
over-represented in TEN group (37.3%, n = 28) when compared
to the CON group (19.4%, n = 19) (p = 0.010, OR = 2.5, 95% CI
1.2 to 4.9). The differences in the genotype (figs 2B and 2C) or
allele (figs 2E and 2F) frequency distributions of the MMP3
rs591058 (genotype p = 0.065 and allele p = 0.051) and rs650108
(genotype p = 0.093 and allele p = 0.368) between the CON and
TEN groups were not significant. But the CC genotype of SNP
rs591058 was over-represented in the TEN (35.6%, n = 26)
compared to the CON (19.6%, n = 19) (p = 0.023, OR = 2.3,
95% CI 1.1 to 4.5) and the AA genotype of SNP rs650108 was
over-represented in the TEN (9.5%, n = 7) compared to the
CON (2.1%, n = 2) (p = 0.043, OR = 4.9, 95% CI 1.0 to 24.1).
Similar results were obtained when the 10 RUP subjects with a
history of tendinopathy were included in the analysis as part of
the TEN group (results not shown).
There were, however, no significant differences in the
distribution of the genotype (rs679620, p = 0.666; rs591058,
p = 0.734; and rs650108, p = 0.627) (figs 2A, 2B and 2C) and
Table 1 PCR primers and probes used for genotyping
SNP Primers (forward/reverse) Probes
rs591058 GAGCAGCAACGAGAAATAAATTGGT VIC-CTATTGTTCTCGATTTCT
GCAGACCTGTGTAATGCACATG FAM-ATTGTTCTCAATTTCT
rs679620 TGTAAGAGTGACCTAAAAACT-
ATACTTATTCTGTTAGA
VIC-AACTACTACGAC-
CTCAAAAA
CCACTGTCCTTTCTCCTAACAAACT FAM-AACTACTACGA-
CCTCGAAAA
rs650108 CATCATTATCAGGTAGAGGTGACAAGT VIC-CAAGGGCTACTTCTAAC
CTCATTGTGTGTTTGTTTTGTCTTCCT FAM-AAGGGCTACCTCTAAC
Primer and probe sets were incorporated into a PCR mastermix and used as described
in materials and methods.
SNP, single nucleotide polymorphism.
Table 2 Characteristics of the control (CON), Achilles tendinopathy
(TEN) and Achilles rupture (RUP) subjects
CON TEN RUP p Value{
Age (years)* 36.8 (9.9),
n = 91
40.5 (13.7),
n = 70
40.7 (11.5),
n = 37
0.078
Height (cm) 176 (10),
n = 95
177 (9),
n = 66
175 (8),
n = 37
0.623
Weight (kg) 72.0 (12.1),
n = 97
78.4 (14.1),
n = 69
85.2 (15.4),
n = 37
,0.001{
BMI (kg/cm2) 23.3 (2.8),
n = 95
24.9 (3.4),
n = 66
27.8 (3.7),
n = 37
,0.001{
Gender (% males) 67.0, n = 97 73.0, n = 74 73.0, n = 37 0.644
Country of birth
(% South Africa)
74.2, n = 97 73.2, n = 71 78.4, n = 37 0.837
Gender and country of birth are summarised as a percentage (%), while the remaining
variables are expressed as mean (standard deviation). BMI, body mass index.
*The age of the TEN and RUP groups are the age of the onset of the initial symptoms
of Achilles tendon injury, which were on average 7.8 (SD 8.0) and 7.5 (SD 8.9) years
prior to recruitment in this study respectively.
{p Value = Global, so CON vs TEN vs RUP.
{Except for the weight difference between the TEN and RUP groups (p = 0.033), all
other pairwise differences in weight and BMI were highly significant (p,0.01).
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allele (rs679620, p = 0.527; rs591058, p = 0.604; and rs650108,
p = 0.840) (figs 2D, 2E, 2F) frequencies of the three MMP3 SNPs
between the CON and RUP groups. The three MMP3 SNP
genotype distributions within the CON, TEN and RUP groups
were in Hardy-Weinberg equilibrium. Although there was a
reduction in statistical power, similar genotype distributions
were nevertheless observed when only the South African born
subjects were analysed (results not shown).
Linkage disequilibrium and inferred haplotype analysis of MMP3
The two SNPs rs679620 (A/G) and rs591058 (T/C) are in almost
perfect linkage disequilibrium (LD), allele G in the former
corresponds to allele C in the latter, with only one heterozygous
individual for rs679620 being TT for rs591058. The D9 measure
was 1 (p,0.001) and the coefficient of correlation, r, was 0.98.
Both SNPs were also in high LD with rs650108, D9= 1
(p,0.001). The coefficient of correlation of rs650108 is 20.57
and 20.58 with rs679620 and rs591058 respectively (figure 3A).
Similar values were obtained when the CON, TEN and RUP
subjects were analysed separately (results not shown).
As expected only the AT and GC haplotypes were inferred
with a frequency greater than 1% from SNPs rs679620 and
rs591058. Since the GG and CC genotypes of these SNPs were
over-represented in the AT group (figs 2A and 2B), the GC
haplotype was over-represented in this group (47% CON vs 59%
TEN, p = 0.031). Since both these MMP3 SNPs were also in high
LD with rs650108 (fig 3A), only three of the eight possible
haplotypes (ATG, GCA and GCG) containing the three SNPs
were inferred with a frequency more than 1%. The ATG
haplotype (53% CON vs 41% TEN) was significantly under-
represented in the TEN group (p = 0.038) (fig 3B).
MMP3 and COL5A1 gene-gene interaction
September et al10 have previously shown that the CC genotype
of the COL5A1 BstUI RFLP (rs12722) was under-represented in
patients with chronic AT. MMP3 SNP rs679620 together with
the COL5A1 SNP formed the best pair of genotypes for
estimating risk for AT. The genotype pairs together with their
frequencies and estimated risk are summarised in table 3. The
MMP3 rs679620 A allele (AA or AG genotype) combined with
the COL5A1 rs12722 CC genotype had the lowest risk for AT.
All the possible A and C allele combinations were associated
with the lowest risk. In support of this, the MMP3 rs679620 G/
A and COL5A1 rs12722 C/T allele combinations (pseudo-
haplotypes) were significantly associated with TEN and CON
status (global-stat = 10.4, df = 3, p = 0.016) (fig 4). The A+C
allele combination was significantly associated with the
controls (30% CON vs 15% TEN, p = 0.002), while the G+T
allele combination was significantly associated with TEN (25%
CON vs 36% TEN, p = 0.006).
DISCUSSION
We report the first evidence that sequence variation within the
MMP3 gene is associated with AT. The data also demonstrate
that a significant interaction exists between the exonic MMP3
SNP (rs679620) and the COL5A1 39-untranslated region
(rs12722) polymorphism and risk of AT. Our data do not
support significant association between MMP3 variants alone,
Figure 2 Relative genotype (A–C) and allele (D–F) frequencies of the MMP3 single nucleotide polymorphisms (SNPs) rs679630 (A and D), rs591058
(B and E) and rs650108 (C and F) for the asymptomatic control (CON, clear bars), chronic AT (TEN, solid bars) and Achilles rupture (RUP, hatched bars)
groups. (A) rs679620: TEN vs CON, p = 0.031; RUP vs CON, p = 0.666; (B) rs591058: TEN vs CON, p = 0.065; RUP vs CON, p = 0.734. (C) rs650108:
TEN vs CON, p = 0.093; RUP vs CON, p = 0.627. (D) rs679620: TEN vs CON, p = 0.037; RUP vs CON P = 0.500. (E) rs591058: TEN vs CON,
P = 0.051; RUP vs CON, p = 0.592. (F) rs650108: TEN vs CON, p = 0.368; RUP vs CON, p = 0.754. The asterisks and solid lines represent specific
genotype (A) GG, p = 0.010; (B) CC, p = 0.023; (C) AA, p = 0.043; or allele (D) G, p = 0.037; significant differences between the TEN and CON groups.
The number (n) of subjects (A to C) or alleles (D to F) are in parenthesis. CON, control group; RUP, Achilles tendon ruptures; TEN, tendinopathy.
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or in combination with the COL5A1 variant, and Achilles
tendon rupture. This suggests there are different inherent
predispositions to both AT and Achilles rupture. Interestingly, a
similar observation has been recently reported with a RFLP in
the COL5A1 gene that is associated with AT but not with
ruptures.9
The apparent dissociation in genetic influence between AT
and rupture is intriguing. It is known that tissue obtained
during surgery to repair an acute Achilles rupture will reveal
evidence of pre-existing tendon pathology.26 In contrast it has
been proposed that acute tendinopathy may occur by different
molecular mechanisms associated with the ageing of ‘‘normal’’
tendon tissue27 28 and hence may explain a different genetic
predisposition to that of acute rupture. This hypothesis would
challenge the assumption that similarities in gross histological
appearances have the same underlying molecular mechanism of
injury although this requires further investigation and verifica-
tion.
All three MMP3 polymorphisms (rs679620, rs591058 and
rs650108) investigated in this study have been found to
associate with AT. As single loci, the rs679620 polymorphism,
GG genotype, and rs591058 polymorphism, CC genotype, co-
segregate with AT with odds ratios of 2.5 and 2.3 respectively.
The rs650108 SNP, AA genotype has a higher odds ratio (4.9)
but only seven cases possessed this genotype due to its low allele
frequency in the population. When analysed as an inferred
haplotype the ATG sequence combination of these three SNPs is
significantly under-represented in AT cases compared to
controls and it may be that this haplotype protects against
the development of AT. Genotype and allele frequencies of the
three SNPs investigated in this study were similar to previously
reported values from databases hosted by the NCBI and
Ensembl as well as from Beyzade et al.17
Figure 3 (A) Linkage disequilibrium (LD) structure of the three single
nucleotide polymorphisms (SNPs), rs679620, rs591058 and rs650108,
within the MMP3 gene. The LD map was constructed using the
combined genotype data from the two Achilles tendon pathology and
control groups. As indicated in colour key, the strength of LD between
any two SNPs is indicated by the colour of the cells. The D9 values,
sample sizes (n) and the coefficient of correlations (r) between pairs of
markers are given within each cell. A positive correlation (r) represents
major alleles being associated with each other, while a negative
correlation (r) means the major allele of the one SNP is associated with
the minor allelle of the other and vice versa. (B) Inferred haplotype
frequency distributions from MMP3 rs679620, rs591058 and rs650108
in the control (CON, clear bars) and AT (TEN, solid bars) groups. Global
P = 0.144. The asterisk and solid line marks the significant difference
(p = 0.038) between the ATG haplotype pair. The number (n) of subjects
in each group is in parenthesis.
Figure 4 The relative distribution of the allele combinations of MMP3
SNP rs679620 (A/G) and COL5A1 SNP rs12722 (C/T) for the control
(CON, clear bars) and Achilles tendinopathy (TEN, solid bars) groups.
Global stat = 10.4, df = 3 and p = 0.016. The asterisk and solid line
marks the significant difference between the allele combination pairs.
AC, p = 0.002 and GT, p = 0.006. The number (n) of subjects in each
group is in parenthesis.
Table 3 The MMP3 rs679620 G/A and COL5A1 rs12722 C/T genotype
pairs, together with their frequencies within the chronic Achilles
tendinopathy (TEN) and control (CON) groups, as well as their estimated
risk (OR) and the risk order
MMP3 COL5A1* CON (98) TEN (74) OR Risk order
GG TT 3.1 (3) 10.8 (8) 3.48 8
GG TC 12.2 (12) 20.3 (15) 1.66 6
GG CC 4.1 (4) 6.8 (5) 1.66 7
AG TT 21.4 (21) 23.0 (17) 1.07 5
AG TC 16.3 (16) 16.2 (12) 0.99 4
AG CC 18.4 (18) 4.1 (3) 0.22 1
AA TT 1.0 (1) 5.4 (4) 5.40 9
AA TC 15.3 (15) 9.5 (7) 0.62 3
AA CC 8.2 (8) 4.1 (3) 0.50 2
The CON and TEN values are represented as a frequency (%) with the number of
subjects (n) in parenthesis.
*The CC genotype is under-represented in TEN subjects.10
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Although our investigation has focused on variation within
the MMP3 gene and predisposition to AT, a number of previous
studies have found that the expression of MMP3 RNA is
reduced in both degenerative20 and ruptured Achilles samples.29
However, why this occurs is still not fully understood but
reduction in MMP3 RNA or protein, without a corresponding
drop in the tissue inhibitors of metalloproteins (TIMPS), might
lead to an increase in proteoglycans30 which have been
documented in degenerative tendons.31 Although reduced
MMP3 expression or activity might lead to tendon pathology,
elevated levels of MMP3 may also underlie predisposition to
tendinopathy. This idea is supported by the observation that
the fluoroquinolone based antibiotic ciprofloxacin, which can
induce Achilles tendon pain and rupture in some individuals,32
has also been reported to substantially increase MMP3 RNA in
IL-1b treated human tendon cells in culture.33
It must be remembered, of course, that allelic association to a
trait or disease does not necessarily infer cause. Accordingly, this
study does not address possible mechanisms of how the MMP3
polymorphisms, alone, as a haplotype, or in the case of
rs679620, in combination with the COL5A1 rs12722 SNP
(BstUI RFLP), might lead to pathology. However, the
rs679620 variant of MMP3 is a non-synonymous polymorph-
ism. Specifically, a glutamate residue is coded for by possession
of the G allele (GAA codon) at the rs679620 loci and a lysine
residue is encoded for by the A allele (AAA codon).34 Although
both residues are polar the glutamate side chain is negatively
charged compared to the positive charge on lysine.35 The residue
sits at position 45 from the start of the polypeptide chain34 and
the first 82 residues, incorporating the propeptide,36 are cleaved
by a proteinase during the processing of proMMP3 into mature
MMP3.37 It might be possible that appropriate removal of the
propeptide has some dependency on the presence of either a Lys
or Glu at position 45 and hence influence downstream function
of the mature MMP3 enzyme. Beyzade et al17 have however
demonstrated using clustal alignment analysis that although
most of the flanking amino acids are conserved across species,
the Glu45 amino acid is not.
It is possible that this association is due to genetic linkage
between the non-synonymous MMP3 polymorphism
(rs679620) and other polymorphisms within the MMP3 gene
and flanking sequences. In support of this, the three SNPs
investigated in this study, which spanned most of the gene,
were in high linkage disequilibrium (D9= 1) with each other. In
addition a SNP within exon 2 of the MMP3 gene is also tightly
linked (D9.0.9) to the well characterised functional 21612 2/T
(5A/6A) and 21986 A/G polymorphisms within the promoter.17
The transcriptional activity of the 5A allele is higher than the
6A allele.16 Based on our and other investigator’s linkage data
within this locus,17 we speculate that the non-synonymous SNP
rs679620 investigated in this study is in high linkage disequili-
brium with the functional 1612 2/T (5A/6A) polymorphism.
Of the 23 MMPs in humans, nine of their genes form a cluster
on the long arm of chromosome 11. The MMP3 gene is part of
this cluster and due to the nature of genetic association studies
we can not exclude that one of the other eight MMP genes are
involved in the pathogenesis of AT. Recently Ye et al18 have
demonstrated that variants within MMP3, together with three
other MMP genes within this cluster, namely MMP-7, -12 and
-13, are associated with rheumatoid arthritis.
Our data demonstrate that the MMP3 variants investigated
in this study interact with the COL5A1 rs12722 polymorphism
in modifying the risk of AT. Although AT is likely to be a
complex condition involving a number of gene-gene and
gene-environment interactions21 there have so far been no such
reports of any gene-gene interactions that relate to increased
risk of AT. At present we are unable to provide a detailed
mechanistic explanation for the interaction of MMP3 variants
with the rs12722 polymorphism of COL5A1 but it is interesting
to note that type V collagen is a reported substrate for MMP314
and may influence its synthesis and activation.38 Hence,
individuals that carry risk variants within both of these genes
may disrupt possible interactions between type V collagen and
MMP3 during catalysis leading to a heightened risk of AT.
Furthermore, future studies might attempt to establish whether
there is differential expression of the MMP3 and COL5A1 genes
in tendinopathy patients carrying the G and T alleles of SNPs
rs679620 and rs12722, respectively, when compared to non-
carriers. This data would assist in establishing whether these
genes are causally implicated in AT.
In addition to the genetic factors identified in this and other
studies,8–10 non-genetic intrinsic factors, as well as extrinsic
factors, have been implicated in the aetiology of Achilles tendon
pathology.39 As previously discussed8 we cannot exclude the
possibility that an interaction of weight and/or physical activity
exposure with the susceptibility genotype was responsible for
the development of Achilles tendon pathology symptoms.
A limitation of this study was that the symptomatic subjects
were significantly heavier than the control subjects. Since this
was a retrospective study, the body weight of the subjects at the
time of injury is unknown. Anecdotally, many subjects reported
increases in their body weight after injury as a result of a
decrease in physical activity. An additional limitation of this
study was the modest sample size.
In conclusion, we report the first evidence that variation
within the human MMP3 gene is associated with AT. We have
also established, for the first time, that the MMP3 variants we
have studied interact with a variant within the COL5A1 gene to
increase risk of AT. We suggest repetition of this work in other,
larger population studies to confirm our associations.
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What is already known about this topic
Both TNC and COL5A1 gene variants have been associated with
an increased risk of Achilles tendinopathy.
What this study adds
Our data demonstrate, for the first time, that variants within the
matrix metalloprotein 3 gene (MMP3) can significantly modify the
risk of tendinopathy. We also show that a variant within the
COL5A1 gene interacts with MMP3 variants to modify risk.
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